DV
Dividend Vision

CLRB — Cellectar Biosciences Inc

Cellectar Biosciences Inc (CLRB)

Its deepest 1-year drawdown was 63.9%.

Cellectar Biosciences is a clinical biopharmaceutical company focused on developing drugs for cancer treatment, with its lead candidate CLR 131 currently in multiple Phase 2 clinical studies for blood cancers and earlier-stage studies for solid tumors and pediatric cancers. The company does not currently distribute dividends. Cellectar appeals primarily to investors seeking exposure to early-stage biotech development rather than income generation.

CLRB key facts

Asset type
Stock
Asset class
Equity
Inception date
06/14/2005
Last close
$2.60
Market cap
$20,059,448
Average volume
46622.0
Payment date
07/17/2018
Beta
0.545
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.38